[ad_1]
Margo Georgiadis, Former CEO of Ancestry and President of Americas at Google, is Appointed Chief Govt Officer
The Firm’s CONECTA™ Platform {Couples} Advances within the Digitization of Pure Chemistry and Human Biology with Highly effective Computational Instruments to Quickly and Repeatedly Establish Drug Candidates
After Three Years of Growth, Flagship Commits an Preliminary $50 Million to Montai
CAMBRIDGE, Mass., Dec. 13, 2022 /PRNewswire/ — Flagship Pioneering, the bioplatform innovation firm, in the present day unveiled Montai Well being, an organization unlocking the ability of nature with its CONECTA™ platform to create medicines that deal with and preempt a broad vary of power ailments. Flagship has initially dedicated $50 million to help the event of Montai’s platform and its preliminary pipeline of recent medicines. The corporate additionally introduced that Margo Georgiadis, MBA, Flagship Pioneering CEO-Accomplice, who beforehand served because the CEO of Ancestry and President of the Americas at Google, is main Montai as CEO.
Montai is constructing the world’s first Anthromolecule™ Bioactivity Atlas based on a privileged class of molecules with an extended historical past of secure, power human consumption. There are greater than 100,000 identified molecules that people have consumed by means of meals, dietary supplements, and natural medicines, together with 40 molecules already present in well-known drugs with a historical past of secure long-term use for ailments akin to Parkinson’s, bronchial asthma, and coronary heart illness. Montai’s CONECTA platform identifies and maps Anthromolecule bioactivity on illness pathways, enabling the fast growth of therapeutics that may potently modulate illness and are secure, efficient, and accessible for earlier intervention and long-term use.
“With Montai, we’re asking the query – what if the important thing to preempting or treating power illness exists inside molecules we already devour,” stated Noubar Afeyan, Ph.D., Co-Founding father of Montai Well being and Founder and CEO, Flagship Pioneering. “Montai’s platform leverages quickly rising developments within the digitization of pure chemistry and human biology coupled with highly effective computational instruments for linking chemical construction and bioactivity. We consider that Montai unlocks the great untapped potential to convey safer, extra tolerable therapeutics to sufferers extra shortly than ever earlier than.”
“To enhance well being outcomes for individuals dwelling with power illness, we should reset the present drug growth paradigm and discover methods to intervene as early potential with secure, long-term options,” stated Ara Darzi, M.D., Chairman of Montai Well being and Chair, Flagship Pioneering Preemptive Well being and Drugs Initiative. “Margo’s expertise main a number of the world’s most cutting-edge firms targeted on information, know-how, science, and consumer-centric healthcare approaches makes her effectively positioned to appreciate these daring aspirations for Montai.”
“Greater than two billion individuals globally are affected by a number of power ailments, creating an unsustainable healthcare system and societal burden,” stated Margo Georgiadis, Co-Founder and CEO of Montai Well being and CEO-Accomplice, Flagship Pioneering. “We’re taking a novel human-centric strategy, constructing the world’s first complete Anthromolecule Bioactivity Atlas, to quickly and repeatedly develop secure, efficacious, and accessible medicines to enhance well being outcomes for as many individuals as potential.”
Together with Noubar Afeyan and Margo Georgiadis, Montai’s founding crew consists of Flagship’s Ignacio Martinez, board member, Hok Hei Tam, Ph.D., Chief Know-how Officer, David Kolesky, Ph.D., Chief Innovation Officer, and Michael Wong, Ph.D., Head of Program Operations & Technique.
About Montai Well being
Montai Well being is targeted on unlocking the ability of nature to create Anthromolecule™ medicines that deal with and preempt a broad vary of human ailments, with an preliminary concentrate on inflammatory and autoimmune illness. Montai’s CONECTA™ platform comprehensively maps Anthromolecule bioactivity throughout pathways that drive illness. The CONECTA platform leverages fast and ever-growing developments within the digitization of pure chemistry and human biology coupled with highly effective computational instruments for linking chemical construction and bioactivity. This confluence of biotechnologies permits Montai to construct a robust, one-of-a-kind discovery platform targeted on creating secure, efficient, and extra human-centric medicines than ever earlier than. Montai Well being was based in Flagship Labs in 2019. For extra info, please go to www.montai.com.
About Flagship Pioneering
Flagship Pioneering conceives, creates, sources, and develops first-in-category bioplatform firms to rework human well being and sustainability. Since its launch in 2000, the agency has, by means of its Flagship Labs unit, utilized its distinctive hypothesis-driven innovation course of to originate and foster greater than 100 scientific ventures, leading to greater than $100 billion in mixture worth. So far, Flagship has deployed over $3.1 billion in capital towards the founding and progress of its pioneering firms alongside greater than $19 billion of follow-on investments from different establishments. The present Flagship ecosystem includes 42 transformative firms, together with Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Agriculture, Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), and Seres Therapeutics (NASDAQ: MCRB).
Media Contact:
[email protected]
SOURCE Flagship Pioneering
[ad_2]
Source link
